These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10513773)

  • 21. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V.
    Reynolds HR; Farkouh ME; Lincoff AM; Hsu A; Swahn E; Sadowski ZP; White JA; Topol EJ; Hochman JS;
    Arch Intern Med; 2007 Oct; 167(19):2054-60. PubMed ID: 17954798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Facilitated PCI in patients with ST-elevation myocardial infarction.
    Ellis SG; Tendera M; de Belder MA; van Boven AJ; Widimsky P; Janssens L; Andersen HR; Betriu A; Savonitto S; Adamus J; Peruga JZ; Kosmider M; Katz O; Neunteufl T; Jorgova J; Dorobantu M; Grinfeld L; Armstrong P; Brodie BR; Herrmann HC; Montalescot G; Neumann FJ; Effron MB; Barnathan ES; Topol EJ;
    N Engl J Med; 2008 May; 358(21):2205-17. PubMed ID: 18499565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
    Bush HS
    J Emerg Med; 2003 Nov; 25(4):421-6. PubMed ID: 14654184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
    Ellis SG; Tendera M; de Belder MA; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Savonitto S; Adamus J; Peruga JZ; Hamankiewicz M; Pluta W; Oldroyd K; Ecollan P; Janssens L; Armstrong P; Brodie BR; Herrmann HC; Montalescot G; Neumann FJ; Effron MB; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2009 Oct; 2(10):909-16. PubMed ID: 19850248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial.
    de Lemos JA; Gibson CM; Antman EM; Murphy SA; Morrow DA; Schuhwerk KC; Schweiger M; Coussement P; Van de Werf F; Braunwald E;
    Am Heart J; 2001 Apr; 141(4):592-8. PubMed ID: 11275925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.
    Antman EM; Giugliano RP; Gibson CM; McCabe CH; Coussement P; Kleiman NS; Vahanian A; Adgey AA; Menown I; Rupprecht HJ; Van der Wieken R; Ducas J; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Circulation; 1999 Jun; 99(21):2720-32. PubMed ID: 10351964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
    Tepe G; Hopfenzitz C; Dietz K; Wiskirchen J; Heller S; Ouriel K; Ziemer G; Claussen CD; Duda SH
    Radiology; 2006 Jun; 239(3):892-900. PubMed ID: 16641342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
    Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
    N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty.
    Petronio AS; Musumeci G; Limbruno U; De Carlo M; Baglini R; Paterni G; Grazia Delle Donne M; Caravelli P; Nardi C; Mariani M
    Am Heart J; 2002 Feb; 143(2):334-41. PubMed ID: 11835040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reteplase with or without abciximab for peripheral arterial occlusions: efficacy and adverse events.
    Hull JE; Hull MK; Urso JA
    J Vasc Interv Radiol; 2004 Jun; 15(6):557-64. PubMed ID: 15178715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
    Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction.
    Ndrepepa G; Mehilli J; Schwaiger M; Nekolla S; Schmitt C; Dirschinger J; Schömig A; Kastrati A
    J Thromb Thrombolysis; 2004 Jun; 17(3):191-7. PubMed ID: 15353917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
    Hasdai D; Holmes DR; Topol EJ; Berger PB; Criger DA; Hochman JS; Bates ER; Vahanian A; Armstrong PW; Wilcox R; Ohman EM; Califf RM
    Eur Heart J; 1999 Jan; 20(2):128-35. PubMed ID: 10099909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of abciximab after failed thrombolytic therapy.
    Cantor WJ; Kaplan AL; Velianou JL; Sketch MH; Barsness GW; Berger PB; Ohman EM
    Am J Cardiol; 2001 Feb; 87(4):439-42, A4. PubMed ID: 11179529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.
    Drescher P; Crain MR; Rilling WS
    J Vasc Interv Radiol; 2002 Jan; 13(1):37-43. PubMed ID: 11788692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.